- Heartflow, Inc. is a leader in AI technology for coronary artery disease (CAD), utilizing over 160 million annotated CTA images and serving over 1,800 institutions globally.
- In the past year, Heartflow filed a patent infringement lawsuit against Cleerly, seeking damages for unauthorized use of its technology, and reported a 40% revenue increase in Q4 2025, reaching $49.1 million.
- Heartflow's technology has been adopted by Cardiovascular Associates of America (CVAUSA), enhancing cardiovascular diagnostics for over 1.3 million individuals annually, and recently gained coverage from Aetna for its Plaque Analysis product.
- The ideal buyer for Heartflow's solutions includes healthcare providers and cardiologists seeking advanced, non-invasive diagnostics for CAD, addressing the need for accurate detection and improved patient outcomes.
Sales and Support is Heartflow’s largest function at 142 employees, accounting for about 28 % of total headcount. Finance and Administration and Engineering each employ 108 people, or roughly 21 % apiece, underscoring the blend of operational and technical expertise required for a medical technology platform. Mid-sized groups include Business Management (7 %) and Marketing and Product (6 %), while Information Technology and Healthcare contribute about 4 % each. Human Resources, Risk/Safety/Compliance, and a small “Other” category round out the organization, each representing between 2 % and 4 % of staff.
Heartflow’s workforce is widely distributed, with 315 employees—around 62 % of the total—listed under “Other,” reflecting a large remote or decentralized component. Among defined sites, Austin, TX hosts the largest concentration at 62 employees (12 %), followed by San Francisco, CA with 43 employees (9 %). Additional hubs include San Jose, CA (4 %), Redwood City, CA (4 %), and New York, NY (3 %). Smaller clusters operate in Mountain View, CA and Pittsburgh, PA (about 2 % each), while Boston, MA and Portland, OR maintain lean teams of 1–2 % of the overall staff.
